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Abstract
Background: In HIV infection, initiation of treatment is associated with improved clinical outcom and reduced rate of sexual
transmission. However, difficulty in detecting infection in early stages impairs those benefits. We determined the minimum
testing rate that maximizes benefits derived from early diagnosis.
Methods: We developed a mathematical model of HIV infection, diagnosis and treatment that allows studying both
diagnosed and undiagnosed populations, as well as determining the impact of modifying time to diagnosis and testing
rates. The model’s external consistency was assessed by estimating time to AIDS and death in absence of treatment as well
as by estimating age-dependent mortality rates during treatment, and comparing them with data previously reported from
CASCADE and DHCS cohorts.
Results: In our model, life expectancy of patients diagnosed before 8 years post infection is the same as HIV-negative
population. After this time point, age at death is significantly dependent on diagnosis delay but initiation of treatment
increases life expectancy to similar levels as HIV-negative population. Early mortality during HAART is dependent on
treatment CD4 threshold until 6 years post infection and becomes dependent on diagnosis delay after 6 years post
infection. By modifying testing rates, we estimate that an annual testing rate of 20% leads to diagnosis of 90% of infected
individuals within the first 8.2 years of infection and that current testing rate in middle-high income settings stands close to
10%. In addition, many differences between low-income and middle-high incomes can be predicted by solely modifying the
diagnosis delay.
Conclusions: To increase testing rate of undiagnosed HIV population by two-fold in middle-high income settings will
minimize early mortality during initiation of treatment and global mortality rate as well as maximize life expectancy. Our
results highlight the impact of achieving early diagnosis and the importance of strongly work on improving HIV testing
rates.
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Introduction
In the last twenty years, development of new antiretroviral drugs
for HIV infection has improved the effectiveness of treatment.
This has led to a delay in AIDS progression, a reduction in
mortality rates, and a partial restoration of the immune system in
infected individuals through normalization of the CD4-count
[1,2,3,4]. Moreover, clinical trials have shown that early initiation
of antiretroviral therapy reduces rates of sexual transmission [5]
supporting expansion of treatment as a strategy for prevention of
new infection [6,7,8].
However, difficulty in detecting HIV infection in early clinical
stages significantly impairs treatment-derived benefits [9,10], with
late detection being associated with higher risk of morbidity and
mortality, reduced effectiveness of treatment and increased risk of
transmission [11,12,13,14,15,16,17]. In spite of consistent efforts
to increase accessibility to antiretroviral drugs, less than half of
HIV infected individuals actually have access to them. In low- and
middle-income settings an average treatment coverage of 31%
(27%–34%) was reported [18]. Moreover, the majority of
individuals infected with HIV are unaware of their serological
status [18] and previous studies have reported a prevalence of late
presenters of 30–40% in developed settings [9,10,16].
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Inability to detect HIV infection in early stages is mainly
associated with the long asymptomatic stage of the natural
infection together with additional factors like socio-economic
status, social stigma, under-perception of risk and the effectiveness
of testing strategies to overcome those barriers. Furthermore,
because of these limitations there is a significant uncertainty
regarding clinical and epidemiological features of the hidden
undetected population living with HIV which in turn leads to
uncertainty about the global HIV epidemic [18].
In the present study we develop a Markov model of infection,
diagnosis and treatment that allows predicting clinical status of
patients at different stages of infection and treatment as well as
estimating global mortality rates and life expectancy for people
living with HIV. By running the model under different initial
conditions we determine the impact that reductions in the time to
diagnosis, different algorithms for initiating treatment and
different efficiencies of detecting HIV infection can have on
infection outcomes. Finally, we determine the HIV detection rates
that maximize treatment-derived benefits.
Materials and Methods
Model Design
We used a Markov model built in TreeAge Pro Suite v.1.0.2.
Sources of data are detailed in table 1 and explained in more detail
in Text S1. The model is composed of 9 mutually exclusive states
represented in Figure 1: the state (i) ‘‘HIV negative population’’
contains all the uninfected individuals, the states (ii) ‘‘Not diagnosed -
Acute Infection’’, (iii) ‘‘Not diagnosed – CD4.250’’, (iv) ‘‘Not diagnosed –
CD4,250’’ and (v) ‘‘Not diagnosed – AIDS’’ represent the HIV
positive undiagnosed individuals at different stages of infection.
The following states group diagnosed individuals according to
treatment stage: the state (vi) ‘‘Diagnosed – Not treated HIV infection’’
includes all the diagnosed but yet untreated HIV positive
individuals, the state (vii) ‘‘Diagnosed infection on early HAART’’
includes all the diagnosed patients in the first 6-months of therapy
under any of the three available HAART regimens, the state (viii)
‘‘Diagnosed infection under suppressive therapy’’ includes all the
diagnosed patients successfully treated (maintaining viral load
under 400 copies/ml) and the state (ix) ‘‘Diagnosed infection under non-
suppressive therapy’’ includes all diagnosed patients under non-
suppressive therapy (because of treatment failure before scheduled
viral load or because of unavailability of a new HAART regimen
after several treatment failures).
Analytical Approach
The Markov model is run in a sequence of cycles. In the present
model each cycle represents a time step of one month and each
simulation lasts 1,800 cycles in order to allow the simulation to
converge. At each cycle, transitions between the 9 mutually
exclusive states described above are determined by rates, logical
rules, and probabilities dependent on individual-level parameters.
In this sense, individual-level simulations were performed by
applying a Monte-Carlo method of analysis. This not-determin-
istic method provides more flexibility compared to standard
Markov cohort analyses since by using tracker variables it retains
memory of previous events from one cycle to the next. A total of
10,000 simulations were run per analysis.
Initial Conditions for the Model
Individuals enter the model homogeneously distributed across
the 1,800 cycles of simulation. The ‘‘entering cycle’’ is recorded as
the moment of infection and defines the initiation of the simulation
of a ‘‘patient’s life’’. At that cycle, each patient is linked to an initial
value of CD4 count (8006200 cells/ml), viral load (4.661.0
Log10[copies/ml]) and age (18 to 56, [19]) sampled from observed
distributions of CD4 count in healthy patients, viral load at the
chronic stage of natural infection and age at the moment of
infection, respectively (see Text S1).
Model Evolution During the Time from Infection to
Diagnosis
During the cycles between the moment of infection and the
moment of diagnosis, the viral load remains constant and the CD4
count diminishes at a rate dependent on the viral load, following a
function adjusted to data published by Mellors et al [20] (Figure
S1). When CD4 count drops below the level of 250 cells/ml a
probability of AIDS progression dependent on the patients age at
the moment of infection, CD4 count, viral load and patients
current age, is applied at each cycle. After progressing to AIDS, a
probability of death associated with HIV infection is applied as
well as a probability of being diagnosed by symptomatology. The
last is further described at follows. A background probability of
dying due to other causes based on general population age-
dependent mortality rates is applied at every cycle.
Modeling HIV Diagnosis
In the present model, HIV positive individuals may achieve
diagnosis through three different routes: (i) in this deterministic
route, individuals are diagnosed when they reach a cycle on the
simulation whose value equals the entering cycle (moment of
infection) plus a pre-defined fixed value (time from infection to
diagnosis), this is, individuals are diagnosed a fixed time after
infection that is the same for every simulation of the same run. (ii)
In this probabilistic route, individuals are diagnosed through
symptomatology. This route is only feasible after an undiagnosed
individual has progressed to AIDS and the probability is defined
by a function dependent on the current CD4 count and pre-
defined for a maximum annual detection rate for patients with
CD4 count lower than 50 cells/ml (see supplemental material). (iii)
In this probabilistic route, HIV diagnosis occurs as a consequence
of applying an annual testing rate over the total undiagnosed HIV
positive population. Combinations of these three routes define the
analytical strategies described as follows.
Analytical Strategies
Simulations were run using two different strategies: In the first
strategy, in order to analyze benefits from earlier diagnoses of HIV
infection, diagnosis routes (i) and (ii) described above were applied,
diagnosis route (iii) was excluded, and the pre-defined fixed value
for ‘‘time from infection to diagnosis’’ was set in each run at a
different value in a range from 2 years to 16 years with 2-year
intervals. In addition, in order to take into account the variability
of outcomes associated with initiating HAART at different CD4
count and detecting AIDS cases through symptomatology with
different efficiencies, each run performed at each fixed ‘‘time from
infection to diagnosis’’ was repeated under each of the 6
combinations of the following situations: Initiating HAART at
CD4 count equal or lower than 200 cells/ml, 350 cells/ml or 500
cells/ml; and diagnosing AIDS through symptomatology with an
efficiency that allows annual detection of 35% or 75% of patients
with AIDS. In a second analytical strategy aimed at understanding
the impact of modifying the annual detection rate, diagnosis route
(i) was excluded (i.e. time from infection to diagnosis was allowed
to vary free) and diagnosis routes (ii) and (iii) were applied. Then
an annual testing rate, defined as the proportion of undiagnosed
individuals that are diagnosed per year was applied to all the
Benefits from Early Diagnosis of HIV Infection
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undiagnosed HIV-positive individuals, independently of their CD4
count, and modified in a range between 0.1 and 50%.
Modeling HIV Treatment
When the diagnosis is achieved, patients remain diagnosed and
untreated until the condition to initiate HAART is satisfied (i.e.
CD4 count lower than a specified value). After initiating
HAART, transitions will be limited to three final stages
containing patients initiating a new or first HAART regimen,
patients under successful therapy and patients under non-
suppressive therapy. During this last phase of the simulation,
rates and probabilities obtained from literature and describing
toxicity of HAART regimens [21], success in achieving
undetectable viral load [22,23,24], discordant responses to
treatment [22] and viral rebound [21] are included. Also, viral
load and CD4 count are modified according to the different
treatment outcomes and in a magnitude that resembles that
previously reported in the literature [2,22,25,26]. In the present
model the number of available HAART regimens is limited to
three, after which the patient is retained in the stage representing
non-suppressive therapy, while viral load is tested on a 6-month
basis frequency. At each cycle of the simulation, CD4-count and
viral load-dependent probabilities of progression to AIDS and
death related to AIDS are applied. A more detailed description
of transition between states can be found in Text S1.
Modeling Disease Progression and Death Rates
The function determining the probability of progression to
AIDS is based in the one previously described by Phillips et al [27],
modified in order to account for patient’s age at the moment of
infection. The probability of progression to AIDS is applied at
every cycle of the simulation. It is not defined a priori but is,
instead, determined by the CD4 count, the viral load and the
patient’s age at each cycle of the simulation. In the model,
individuals can die due to causes related to AIDS and due to
causes not related to AIDS. The former depends on patient’s age
at infection and is only applied after a patient has progressed to
AIDS and until the AIDS condition is resolved. The death rates
not related to AIDS are applied at every cycle of the simulation,
and are derived from age-dependent mortality rates of general
population. A detailed description of these functions can be found
in Text S1 and in Figure S2.
Assessment of Internal Consistency
In order to ensure the mathematical consistence of the model a
lower limit for viral load was set at 1.7 Log10[copies/ml] (which
corresponds to undetectable viral load with a sensitivity of 50
copies/ml), and at 50 cells/ml for CD4 count; as well as an upper
limit for viral load was set at 5.6 Log10[copies/ml], while for CD4
count it was set at the value initially sampled for the CD4 count
previous to infection. These limitations prevent inconsistent
Figure 1. Schematic view of the model structure. This flowchart shows the states that constitute the model, in which individuals can be
classified at any time of the simulation. For additional details on probabilities and logical rules involved in transition between states see supplemental
material.
doi:10.1371/journal.pone.0053193.g001
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Table 1. Detail of the INPUTS for the model.
Expected
value Range Ref.
Constant Variables
Patients age at the moment of infection (year-old) 24 (18 to 56) [19]
Tracker Variables
Initial CD4-count (CD3+CD4+ cells/ml) 800 (600 to 1000) Assumed
CD4 change during viral suppression (cells/ml*year) 60 (40 to 80) [3]
CD4 change after dual response (cells/ml*6 first months of therapy) 148 (102 to 225) [22]
CD4 change after immunologic-only response (cells/ml*6 first months of therapy) 125 (85 to 194) [22]
CD4 change after virologic-only response (cells/ml*6 first months of therapy) 0 0 [22]
CD4 in non-responders (cells/ml*6 first months of therapy) 0 0 [22]
Initial Viral-load (VL; log10[RNA copies/ml]) 0
VL when become infected (log10 [RNA copies/ml]) 4.6 (3.6 to 5.6) [23,24,32,56]
VL at rebound after therapy failure (log10 [RNA copies/ml]) 4.1 (3.6 to 4.6) [25,26]
VL change after dual response (log10RNAcopies/ml*6 first months of therapy) 23.1 (23.6 to 22.5) [22]
VL change after immunologic-only response (log10RNAcopies/ml*6 first months of therapy) 21.6 (22.2 to 20.8) [22]
VL change after virologic-only response (log10RNAcopies/ml*6 first months of therapy) 22.9 (23.4 to 22.2) [22]
VL change in non responders (log10RNAcopies/ml*6 first months of therapy) 20.7 (21.7 to 0) [22]
Functions
VL-dependent decay of CD4-count [20]
Probability of AIDS progression [27,29]
Probability of death from AIDS [28,29]
Probability of detection through symptoms [30]
Rates
CD4 decay factor 14.76 (9.39 to 20.43) [20]
Toxicity in the first 6 months of treatment (% patients experiencing toxicity/treated patients*year) 28.6 (24 to 33.2) [21]
Toxicity after the first 6 months of treatment (% patients experiencing toxicity/treated
patients*year)
15.4 (13.4 to 17.4) [21]
Rebound rate in the first year (% patients failing/successfully treated patients*year) [21]
First HAART regimen 3.1 (2 to 4.2)
Second HAART regimen 6.2 (4 to 8.4)
Third HAART regimen 12.4 (8 to 16.8)
Rebound rate after the first year (% patients failing/successfully treated patients*year) [21]
First HAART regimen 5?2 (4.6 to 5.9)
Second HAART regimen 10?4 (9.2 to 11.8)
Third HAART regimen 20?8 (18.4 to 23.6)
Suppression rate (% patients achieving viral load bellow 400 RNA copies/ml*treated patients*6
first months of therapy)
[22,23,24]
First HAART regimen 75 (65 to 85)
Second HAART regimen 65 (55 to 75)
Third HAART regimen 30 (20 to 40)
Rate of dual response to treatment after suppression (VR+ IR+, % patients achieving undetectable
viral load (,50 RNA copies/ml)/patients successfully suppressing viral load (,400 RNA copies/ml))
67 (50 to 90) [22]
Rate of discordant responses [22]
Immunological not virological response (% patients improving CD4 count/patients not
successfully suppressing viral load)
60 (40 to 80)
Virological not immunological response (% patients reducing viral load between 50–400 RNA copies/ml) 33 (10 to 50)
Risk associated to past AIDS (folds of increased risk) 2.35 (1.48 to 3.71) [21]
Other parameters
Time allowed to maintain the same regimen in spite of not virologic response 6 months Assumed
Frequency of viral-load testing 6 months Assumed
Number of available HAART regimens 3 Assumed
doi:10.1371/journal.pone.0053193.t001
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prediction of variations of CD4 count and viral load while
unlimited reduction in CD4 count or extreme decay rates are
prevented by using a function adjusted to data published by
Mellors et al [20] (see Text S1 for function development and
Figure S1). As mentioned above, the function describing the
probability of progression to AIDS and the probability of death
after AIDS was created based on previously described functions
[27,28] and adjusted with data previously published [29] for taking
into account patients age at the moment of infection. The function
describing the probability of achieving the diagnosis through
symptomatology was defined as a linear function dependent on
CD4 count, based on the one previously described by Sanders et al
[30], but modified to allow a maximum rate of detection of 35% or
75% (DTS efficiency) at CD4 count equal or lower to 50 cells/ml
and a minimum of 0% at CD4 count equal or higher than 350
cells/ml.
Assessment of External Consistency
In order to assess the external consistency, the model was run
under two different situations. In the first one, the possibility of
getting diagnosed was removed and the model was set to sample
individuals’ age at infection from a uniform distribution in order to
have equal numbers of individuals at different age ranges. Then,
the time to AIDS and death were determined by subtracting the
individuals age at infection from the individuals age at disease
progression or the individuals age at death, respectively. Predic-
tions were compared with those previously reported for CAS-
CADE Cohort [29] (see Text S1 and Figures S6, S7, S8 and S9 for
further details). For the second situation, and in order to assess the
external consistency of our model during simulations involving
diagnosis and treatment, populations diagnosis rate was set at 10%
(per 100 undiagnosed HIV-positive persons per year) and a
Kaplan Meier analysis was performed, censoring cases at the
moment of death due to other causes and considering death
related to AIDS as the event. In these simulations, individuals age
at infection were sampled from the distribution previously
reported [19] and individuals who died before achieving diagnosis
or individuals still alive at the end of the simulation were excluded
from the analysis. The function describing age-specific mortality
rates was obtained by deriving the natural logarithm transforma-
tion of the survival curve and the average mortality rate per age
range was estimated by integrating the function between each
analytical range (see Text S1 and Figures S10, S11, S12 and S13
for further details).
Statistical Considerations
The model was run with 10,000 Monte-Carlo simulations of
1,800 cycles per simulation. The majority of outputs were
described by proportions, in which case the 95% confidence
intervals were estimated assuming normal distribution due to the
large number of cases. Confidence intervals for proportion were
also estimated by bootstrap techniques demonstrating identical
results. In all the analyses performed, calculations demonstrated a
power higher than 99% to detect significant differences with an
alpha level of 0.05. For life-expectancy analysis, one-way ANOVA
was performed; homogeneity of variances was assessed by Levenes
test and a-priori defined post-hoc multiple comparisons were assessed
by Bonferronis test.
Results
In order to validate the model, predictions regarding time to
AIDS and death during the natural history of infection as well as
the mortality rate during treatment were compared with data
previously published. As shown in Figure 2, models predictions are
similar to those previously reported for patients without treatment
or under monotherapy, being more accurate for individuals
getting infected before 45-year old. In order to assess the external
consistency of the model during simulations involving diagnoses
and treatment, diagnosis rate was set at 10% (per 100 undiagnosed
HIV-positive persons per year). This testing rate was used because
is the one that most closely resembles observations from high-
income settings as explained later. Then, age-specific survival rates
were obtained from the survival curve for AIDS-related death in
the diagnosed population. As shown in Figure 2, model s
predictions of mortality rate after diagnosis are consistent with
those previously observed.
Next, we analyzed the impact of modifying the diagnosis delays
in mortality rate of the HIV-infected population, including in the
analysis both diagnosed and undiagnosed individuals. For this
analysis, time from infection to diagnosis was set as a fixed factor
and the model was run for 35% and 75% of DTS efficiency and
for 200, 350 and 500 cells/ml treatment CD4 thresholds. The
analyses show that achieving diagnosis during the first eight years
of infection, the annual mortality rate stays stable at an average of
2.5 deaths per 100 infected individuals per year (Figure 3). For
higher delays, this rate significantly increases in a DTS capacity-
dependent manner reaching an average value of 3.8 for an annual
DTS-capacity of 75% and 5.0 for an annual DTS-capacity of
35%. These predictions reflect the fact that when diagnosis is
achieved in early stages of infection patients are not advanced
enough to allow detection-through-symptomatology; while, if
diagnosis is achieved at advanced stages, then the capacity to
detect infection-through-symptomatology plays an important role
in preventing higher rates of mortality. Also, as shown in Figure 3,
the CD4-count threshold at which treatment is initiated does not
impact significantly on the overall mortality rate at the population-
level. Small variations can be observed in the estimations obtained
from runs performed with different treatment CD4 thresholds
under the same diagnosis delay; however those variations are likely
to be related with the probabilistic estimation of the proportion in
the model since none statistically significant difference was
observed.
When patients ages at death obtained from the simulations run
above are analyzed, a strong association between life expectancy
and diagnosis delay can be observed (Figure 4). According to our
results, life expectancy for the total HIV population is increased up
to 27 years comparing individuals diagnosed during the first 8
years of infection with the worst scenario analyzed of 16 years-
delay with a 35% DTS-capacity. An improvement in the DTS-
capacity can significantly increase life expectancy when the
diagnosis is achieved at or after 10 years of infection (6.2 years
when comparing life expectancy at 16 years-delay for both DTS
efficiencies, p,1024). When the analysis is limited to diagnosed
individuals (i.e. excluding individuals who die before diagnosis), life
expectancy variations are lower and less sensitive to diagnosis
delay but still significantly different when the diagnosis is achieved
during the first 12 years of infection compared to a later diagnosis
(Figure 3, p,10211). As was the case for annual mortality rate,
CD4-count threshold at which treatment is initiated does not
impact significantly on the average age at death of patients in our
simulations.
Based on results shown above, the time point of 8 years of
infection seems to be an inflection point: a diagnosis achieved after
8 years of infection leads to significant increases in mortality rate
and a decreased age at death while a diagnosis achieved before
that time of infection leads to a stable mortality rate and a stable
expected age at death, independently of diagnosis delay and
Benefits from Early Diagnosis of HIV Infection
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Figure 2. Comparison of models outputs related to mortality rates with those previously reported. Time to AIDS and time to death as
well as age-dependent AIDS-related mortality rates are compared with those previously reported for the CASCADE cohort and the DHCS cohort.
doi:10.1371/journal.pone.0053193.g002
Figure 3. Annual mortality rate of total individuals living with HIV for each of the analytical settings. The model was run with the
different fixed times from infection to diagnosis detailed in the figure. At the end of each run, the annual mortality rate was determined. Each run was
repeated with the 6 combinations of the three CD4 count threshold to initiate HAART (200, 350 and 500 cells/ml) and two different efficiencies to
detect HIV infection through symptomatology (35% and 75%). *Significantly different with a p-value,0.05.
doi:10.1371/journal.pone.0053193.g003
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suggesting equal benefits derived from diagnoses achieved at any
time point during the first 8 years of infection. However, a strong
dependence of analyzed mortality rate during the first year of
treatment on CD4 count at initiation of HAART was observed: as
shown in Figure 5, mortality rates are significantly higher in
patients for whom treatment initiation was deferred to 200 cells/ml
(2.1% for 2 years-delay) compared with initiation at 350 or 500
cells/ml (0.8% and 0.4% respectively for the same delay, p,0.001).
In addition, the model predicts that after 8 years-delay, this rate
increases abruptly in a linear manner until reaching an average of
5.5 deaths per 100 infected individuals per year at 16 years-delay
in a DTS-capacity independent manner. The association of early
mortality rate with CD4 count at initiation of HAART is lost for
diagnosis delays equal to or higher than 8 years since according to
our prediction after that time of infection patients are diagnosed
harboring a median CD4 count of 200 cells/ml (Figure S3). In this
sense, as the diagnosis delay becomes greater, the proportion of
undiagnosed individuals with CD4 counts at critically lower levels
become higher. As shown in Figure 6, when diagnosis is achieved
later than four years after infection, undiagnosed HIV positive
individuals with CD4 counts lower than 250 or 350 cells/ml starts
to become an increasing proportion of the total undiagnosed
population. Considering our previous results, Figure 6 shows that
if diagnosis is not achieved during the first 8 years of infection, 20–
25% of the undiagnosed population will have a CD4 count lower
than 350 cells/ml and will be therefore excluded from benefits
derived from an earlier initiation of treatment while 10–15% will
be in urgent need of treatment (i.e. CD4 count lower than 250
cells/ml). Although no differences in the composition of the
undiagnosed population can be expected for settings having
different treatment CD4 threshold but the same diagnosis delay,
predictions derived from runs obtained for all the situations are
still shown in Figure 5 as a demonstration of the variability
associated to independent runs.
At the population-level, reduced capacity of diagnosing HIV
positive individuals in early stages of infection leads to a greater
proportion of HIV-positive individuals being unaware of their
infection. In our model, diagnosis delay is directly related to the
proportion of individuals living with undiagnosed infection: The
longer it takes to achieve a diagnosis, the higher the proportion
of individuals living with undiagnosed infection (Figure S4).
Inversely, to increase and sustain testing frequency would lead
to an accumulation of probabilities over time for each individual
to get diagnosed and to the consequent reduction in diagnosis
delay. In this sense, in order to analyze the relationship between
time of infection and testing rate in the undiagnosed population,
the time from infection to diagnosis was allowed to vary free
while the testing rate was set as a fixed factor. Then, the model
was run under different testing rates and the distribution of time
of infection predicted for the undiagnosed population was
analyzed for each rate. As shown in Figure 7, both variables are
related in a non-linear manner. The percentile lines specify the
proportion of undiagnosed individuals with less than a specific
time of infection for each testing rate. When the models outputs
from the simulations using route 3 (fixed testing rate, relaxed
diagnosis delay) are compared with outputs from simulations
using route 1 (fixed diagnosis delay) we observe that predictions
obtained with a specific annual testing rate correspond to those
obtained when diagnosis delay is fixed at the third quartile of
the heterogeneous distribution of diagnosis delays observed for
that rate. In other words, predictions obtained using a specific
fixed diagnosis delay are those expected for a real-world setting
were the 75% of the HIV-positive population is diagnosed
within those first years of infection (Figure S5).
When the relationship between testing rates and diagnosis delay
is analyzed, according to models predictions a median and stable
time to diagnosis between 10 and 11 years is associated with a
testing rate lower than 1%. In that situation, diagnosis is achieved
exclusively though symptomatology at the mentioned rate.
Importantly, according to our predictions, to achieve an annual
testing rate of 20% will allow diagnosis of 90% of HIV-positive
individuals within the first 8 years of infection, which in turn, and
Figure 4. Comparison of average age at death of HIV positive individuals according to the capacity of detecting infection by
symptomatology and the access to treatment. Age at death for the population living with HIV are compared with those individuals who have
achieved diagnosis. Predictions show the impact of early diagnoses on extending life of individuals living with HIV, as well as show that
improvements in efficiency of detecting HIV infections through symptomatology can significantly extend life expectancy in cases where the diagnosis
is achieved later than 8 years post-infection. Predictions show the major impact that access to therapy can have on extending life expectancy even for
patients diagnosed in advanced stages of infection.
doi:10.1371/journal.pone.0053193.g004
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based on our previous predictions, will minimize mortality rate,
maximize life expectancy and achieve diagnosis in a clinical stage
where early mortality at initiation of treatment can be prevented
by treatment strategies based on higher CD4 thresholds.
Discussion
Based on the known impact that treatment has in quality and
expectancy of life of HIV positive individuals, to reach an early
diagnosis and to ensure access to therapy stands as one of the
major goals in the fight against HIV epidemic [31]. While it is
clearly known how strongly dependent on diagnosis delay are the
Figure 5. Mortality rate in the first year of HAART for each of the analytical settings. For the present analysis, the percentage of newly
treated patients that die during the first year of initiation of the first HAART regimen was estimated. In this case, data recovered across the whole
simulation was analyzed by identifying patients that have initiated HAART and whose date of death occurred within the 12 simulation cycles after
initiation of HAART, over the total individuals that have initiated HAART during the model run. *Significantly different with a p-value,0.05.
doi:10.1371/journal.pone.0053193.g005
Figure 6. Proportion of HIV positive individuals unaware of their infection status having CD4 counts below 250 (dark bars) or 350
cells/ml (light bars), for each of the analytical settings. In this case, model’s outputs were further analyzed to determine the proportion of HIV
positive individuals unaware of their infection whose CD4 count have drop below critical levels (250 and 350 cells/ml).
doi:10.1371/journal.pone.0053193.g006
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clinical status of patients at diagnosis and the mortality rates
[9,10,16,17], our model provides a deeper description about the
way they are interrelated.
The present model demonstrates a significant accuracy in
simulating the natural history and treatment outcome of HIV
infection for settings similar to those studied in the CASCADE
Cohort and in the population-based Danish HIV Cohort Study
(DHCS), against which the model was validated. Interestingly, as
shown in Figure 8, when the model is set at a fixed diagnosis delay
of 8 years, the models outputs closely resemble characteristics of
patients observed in high income settings (ART-CC cohort [12]);
while setting the model at a fixed diagnosis delay of 10 years drives
outputs to resemble more closely those observed in low income
settings (ART-LINC [12], CCASAnet in Latin America [32]).
This suggests that the diagnosis delay by itself can play a central
role in determining the epidemiological features observed in
different settings.
However, while mortality rate during the first year of HAART
is also accurately estimated for high-income settings, it is
underestimated for low income settings in our model. As shown
in Figure 8C, being set at a diagnosis delay of 10-years the model
predicts a 3.3% (IC: 2.8–3,8) mortality rate in the first year of
HAART that is significantly different from previous reports from
these settings, which are near to 10%: for ART-LINC it was
reported 6.4% (5.1–7.7) [12], 13% for Haiti [13], 8.3% (7.6–9.1)
for South America [32], 8.9% (8.4–9.5) for South Africa and
Malawi [33], and an average 10% in different studies from Africa
as reviewed by Lawn et al [34]. However, this rate is highly
variable even among similar settings as shown by its variability
within Latin America previously reported by Tuboi et al [32]
(Figure 8C) and might be highly dependent on variations in
background and AIDS-related mortality rates as well as on disease
progression rate or prevalence of comorbidities at baseline, all
characteristics shown to be different between low and high-income
settings [12,32,35] [36]. For example, our model predicts a
mortality rate for untreated population of 10.9% person-year
(10.4–11.5) which derives predictions highly consistent with
middle-high income settings as mentioned above, but studies from
Africa have had reported rates higher than 20% [37,38,39].
Therefore, while model’s predictions can assign a specific diagnosis
delay that explain at the same time several variables observed in
middle-high income settings, this is not possible in our model for
the case of low income settings. As explained above we relate this
fact mainly to differences in mortality rates between those settings
and it also highlights that predictions obtained from our model fit
more adequately to middle-high income settings.
Taking into account these limitations, our predictions still
demonstrate the impact that reducing time from infection to
diagnosis can have in improving clinical outcome and the
consistency with observations from middle-high income settings
shows that the model can provide predictions relevant to real-
world settings. In this sense, our results suggest that an eight year
delay stands as an inflection point between two different settings:
When diagnosis delay is higher than 8 years, overall mortality rates
starts to increase, life expectancy starts to decrease, capacity of
recognizing HIV infection through symptomatology becomes
critical, and benefits derived from not deferring treatment
initiation to lower CD4 counts are lost. In contrast, achieving
Figure 7. Analysis of the impact of detection rate on diagnosis delay. The data was obtained from simulations where the diagnosis delay
was relaxed. Then testing rate was modified and distribution of year of infection in the undiagnosed population was analyzed. In the figure, each
curve corresponds to a different percentile of that distribution. In dark blue is shown the curve for the median.
doi:10.1371/journal.pone.0053193.g007
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diagnosis before 8 years post-infection minimizes mortality rates to
stable levels, maximizes life expectancy and allows prevention of
early mortality through initiation of treatment at higher CD4
counts.
Importantly, our results suggest that ARV-treatment can
recover life expectancy almost to the maximum achievable levels
even when diagnosis delay is extremely long, indirectly demon-
strating the central role that linkage to care after diagnosis plays in
managing HIV infection since, although in our model every
diagnosed patient who meets criteria for treatment initiation has
immediate access to therapy, the effect of a delayed linkage to
treatment can be estimated by moving forward to analytical
settings with larger diagnosis delays. In this sense, a setting with 8
years delay for diagnosis and 1 year delay for linkage-to-care is
equivalent to a 9 years diagnosis delay in terms of patient
prognosis. We can observe from our estimation of patients’ age at
death that even in analytical settings with the larger diagnosis
delays, patients who are diagnosed and linked-to-treatment have
similar life expectancy as those in analytical settings with the
shortest diagnosis delays. Nevertheless, as mentioned above, in the
former settings early mortality is significantly higher than in the
last. Therefore, in order to prevent early mortality associated with
HIV infection, achieving diagnoses within the first 8 years of
infection should stand as the first goal.
It is important to note that the present model is based on
individual disease progression, and as such it does not take into
account transmission. Therefore, benefits derived from preventing
new infections through treatment or behavioral-changes associated
with knowledge of serological status are not modeled here. In this
sense, it is important to highlight that additional population-level
benefits can be expected from reducing diagnosis delays besides
the ones predicted in the present study.
Finally, we analyzed the relationship between time to diagnosis
and testing rate in order to define specific goals for achieving
significant reductions in diagnosis delay. This analysis represents a
key component of the study since it connects the unrealistic route
Figure 8. Comparison of model’s output with observations from different settings. The model was run under a fixed time to diagnosis of 8
years and 10 years. Predictions obtained using a 8-years delay resemble middle-high income settings while those obtained using 10-years delay
resemble low-middle income settings for the proportion of patients with CD4 counts lower than 200 cells/ml (A) and median CD4 count at initiation
of HAART (B). Predictions about mortality rate during the first year of HAART are consistent with middle-high income settings but distant from those
observed in low-middle income settings (C). Latin American cohorts in panel C are those part of CCASAnet cohort.
doi:10.1371/journal.pone.0053193.g008
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of diagnosis where fixed times to diagnosis are applied, with the
more realistic situation of studying variations in testing rates and
relaxing the time from infection to diagnosis. As mentioned above,
the set of predictions obtained under a fixed diagnosis delay are
those expected when the 75% of HIV-positive individuals are
diagnosed before reaching that time point of infection. In
particular, according to our prediction, if an annual testing rate
of 20% is reached, then 90% of infected individuals will achieve
diagnosis within the first 8 years of infection. Although this testing
rate is highly challenging, it may not be unfeasible if we consider
the following analysis: Previous studies have estimated that the
percentage of patients achieving a late diagnosis (defined as
proportion of newly diagnosed individuals with CD4-count lower
than 200 cells/ml) stands close to 30% [27]. Because our model
estimates a time of infection of at least 8 years for patients with
CD4-count lower than 200 cells/ml (Figure S3), we can infer that a
30% of late presenters corresponds with a testing coverage that
allows detection of 70% of patients before 8 years of infection;
which, according to the model, corresponds to a testing rate close
to 10% (Figure 7). Starting from this baseline annual rate of 10%,
to reach a testing rate of 20% that will allow to achieve diagnosis
of 90% of HIV positive population before the first 8 years of
infection may not be an impossible task if we work strongly on
missed opportunities for diagnosis [9,40,41,42], socio-economic
status-related disparities in access to health care, social stigma and
under-perception of risk that discourage people from seeking
testing [16,40,43,44,45,46,47,48,49,50], as well as on implement-
ing more efficient testing strategies [51,52,53,54,55]. The many
demonstrated benefits for the patients, previously reported and
also suggested here, largely justify the effort.
Supporting Information
Figure S1 Viral Load-dependent CD4 count decay. The
linear function adjusted to model the reduction in CD4 count
determined by viral load is shown.
(TIF)
Figure S2 Curves describing rates of disease progres-
sion and death according to variations in viral load, CD4
count and patient’s age. Four different scenarios are shown
according to the patient’s age at the moment of infection.
Although this is a continuous variable, in order to simplify the
explanation only four different ages at infection are shown. For
each situation, variations due to CD4 count, viral load and
patient’s current age are shown. The probability of death can be
obtained by multiplying the probability of disease progression by
0.45, 0.58, 0.72 or 0.85 for 25, 35, 45 and 55 years-old at infection
(see Text S1).
(TIF)
Figure S3 Median CD4 count at initiation of HAART
according to time from infection to diagnosis. Simulations
were run under the following combinations of CD4 count
threshold to initiate HAART and annual rate of detection through
symptomatology (DTS) for the following conditions: Initiation of
HAART at 200 (grey line), 350 (light blue line) and 500 (dark blue
line) cells/ml; and each of them for both annual rate of DTS of
35% and 75%.
(TIF)
Figure S4 Proportion of HIV positive individuals un-
aware of their infection observed at any time in a steady
state situation for each of the analytical settings.
Simulations output from the same model runs analyzed for
Figure 3, were also analyzed to determine the proportion of HIV-
positive individuals unaware of their serological status as those
who did not achieve a diagnosis out of the total of individuals
living with HIV at the end of the simulation. The proportion
determined for a specific analytical setting is stable across the
simulation. As expected, simulations runs that differ only in the
CD4 count threshold to initiate HAART give identical predictions
as different treatment initiation algorithms cannot impact
diagnosis of infection.
(TIF)
Figure S5 Comparison of models output run under
diagnosis route 1 (fixed diagnosis delay) and diagnosis
route 3 (fixed testing rate). For each annual testing rate,
results from using the rate or using the diagnosis delay fixed at the
third quartile (Q75) of the distribution of diagnosis delays are
shown. Comparisons performed for mortality during the first year
of HAART (upper panel), clinical stage at diagnosis and
proportion of patients unaware of their infection (mid panel),
and age at death (lower panel) are shown.
(TIF)
Figure S6 Baseline distributions of variables relevant
for the analysis of models predictions about the natural
history of HIV infection. The distribution of patients age at
infection, CD4 count and viral load are shown.
(TIF)
Figure S7 Patients age at progression to AIDS and death
predicted in by the model in the absence of treatment.
(TIF)
Figure S8 Distribution of the total times to AIDS and
times to death predicted by the model in the absence of
treatment.
(TIF)
Figure S9 Times to AIDS and times to death according
to patients age at infection death predicted by the model
in the absence of treatment.
(TIF)
Figure S10 Baseline distributions for Mortality rates
analysis. Distribution of patients age at infection, patients age at
initiation of HAART, viral load and CD4 count at the moment of
infection are shown.
(TIF)
Figure S11 Patients age at death. Distribution of patients
age at death during the simulations runs to determine the general
mortality rates of HIV-positive individuals after diagnosis.
(TIF)
Figure S12 Survival curves obtained by Kaplan Meier
analysis and their natural logarithmic transformation.
Curves for the total population and separating HIV related death
from other causes of death predicted by the model for HIV-
positive individuals after diagnosis.
(TIF)
Figure S13 Curve fitted to the natural logarithmic
transformation of the survival curve related to AIDS
mortality. Three different functions were adjusted to each of the
three age intervals shown in the figure. Functions details are
provided in Text S1.
(TIF)
Text S1.
(DOC)
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